• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SD filed by Stereotaxis Inc.

    6/2/25 12:07:07 PM ET
    $STXS
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $STXS alert in real time by email
    SD 1 formsd.htm SD

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM SD

    Specialized Disclosure Report

     

    Stereotaxis, Inc.

     

    (Exact name of registrant as specified in its charter)

     

    Delaware   001-36159   94-3120386
    (State or other jurisdiction of   (Commission   (IRS Employer
    incorporation or organization)   File Number)   Identification No.)

     

    710 N. Tucker Blvd, Suite 110; St. Louis, MO   63101
    (Address of principal executive offices)   (Zip Code)

     

    314-678-6100

     

    (Name and telephone number, including area code, of the person to contact in connection with this report.)

     

    Check the appropriate box to indicate the rule pursuant to which this form is being filed, and provide the period to which the information in this form applies:

     

    ☒ Rule 13p-1 under the Securities Exchange Act (17 CFR 240.13p-1) for the reporting period from January 1 to December 31, 2024.

     

     

     

     

     

     

    Section 1 – Conflict Minerals Disclosure

     

    Item 1.01 Conflict Minerals Disclosure and Report

     

    This Specialized Disclosure Report on Form SD (“Form SD”) of Stereotaxis, Inc. (“Stereotaxis”, the “Company” or “we”) for the reporting period from January 1 to December 31, 2024, is filed pursuant to Rule 13p-1 under the Securities Exchange Act of 1934 (the “Rule”). Capitalized terms not otherwise defined herein are defined in the Rule.

     

    Stereotaxis evaluated its products and determined that our products contain “necessary conflict minerals.” This means that Conflict Minerals as defined in the Rule are present in products we manufacture or contract to manufacture and are used to achieve the required function, use or purpose of those products. Our determination and related disclosures relating to such necessary conflict minerals are included in Stereotaxis’ Conflict Minerals Report and are incorporated by reference herein.

     

    Item 1.02 Exhibit

     

    The Company has filed a Conflict Minerals Report as Exhibit 1.01 to this Form SD. Stereotaxis’ Conflict Minerals Report is available at http://www.stereotaxis.com/legal/. The website and the information accessible through it are not incorporated into this Form SD.

     

    Section 2 - Exhibits

     

    Item 2.01 Exhibits

     

    Exhibit 1.01 Stereotaxis, Inc. Conflict Minerals Report for the reporting period January 1 to December 31, 2024

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the duly authorized undersigned.

     

    STEREOTAXIS, INC.    
    (Registrant)    
         
    By: /s/ Patricia S. Williams   June 2, 2025
    Name: Patricia S. Williams   (Date)
    Title: Secretary    

     

     

     

    Get the next $STXS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $STXS

    DatePrice TargetRatingAnalyst
    1/10/2024$5.00Buy
    ROTH MKM
    7/12/2022$6.00Buy
    Aegis Capital
    6/23/2022$6.00Buy
    B. Riley Securities
    1/5/2022$11.00Buy
    Craig-Hallum
    1/5/2022$13.00Buy
    Loop Capital
    More analyst ratings

    $STXS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Financial Officer Peery Kimberly R.

      4 - Stereotaxis, Inc. (0001289340) (Issuer)

      4/10/25 4:05:06 PM ET
      $STXS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Director Isaac Paul J bought $68,780 worth of shares (38,000 units at $1.81), increasing direct ownership by 77% to 87,299 units (SEC Form 4)

      4 - Stereotaxis, Inc. (0001289340) (Issuer)

      3/11/25 3:38:02 PM ET
      $STXS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Director Isaac Paul J bought $44,836 worth of shares (24,788 units at $1.81), increasing direct ownership by 90% to 49,066 units (SEC Form 4)

      4 - Stereotaxis, Inc. (0001289340) (Issuer)

      3/10/25 10:32:20 AM ET
      $STXS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $STXS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Stereotaxis Reports 2025 First Quarter Financial Results

      ST. LOUIS, May 12, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the first quarter ended March 31, 2025. "We've started the year with solid execution on key commercial and innovation efforts," said David Fischel, Chairman and CEO. "This is a milestone rich year in which we are beginning to demonstrate the tangible reality and commercial impact of our comprehensive innovation strategy." "Key commercial advances include recurring revenue growth, initial commercialization of MAGiC in Europe, successful demonstrations of GenesisX as a rapidly

      5/12/25 4:01:00 PM ET
      $STXS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Stereotaxis to Report First Quarter 2025 Financial Results on May 12, 2025

      ST. LOUIS, April 22, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2025 first quarter on Monday, May 12, 2025 at the close of the U.S. financial markets. The Company will host a conference call and webcast at 4:30 p.m. EST that day to discuss the Company's results and corporate developments. What:Stereotaxis first quarter 2025 financial results conference call  When:Monday, May 12, 2025, at 4:30 p.m. ET (1:30 p.m. PT)  Dial In Number:To access the live call, dial 800-715-9871 (US and Canada) or 1-646-307-1963 (International) a

      4/22/25 7:00:00 AM ET
      $STXS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Stereotaxis to Feature First-Ever Live Demo of GenesisX Robotic System at HRS 2025

      ST. LOUIS, April 21, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, announced today it will host a live demonstration of the GenesisX Robotic System at this year's Heart Rhythm Symposium (HRS), taking place April 24 – 27 in San Diego, CA. This marks the first live, public demonstration of GenesisX, offering a glimpse to HRS attendees into the robot's revolutionary clinical capabilities and "weekend" installation. GenesisX represents the latest advance in endovascular surgical robotics, building upon the proven benefits of Robotic Magnetic Navigation while significantly enhancing accessibi

      4/21/25 8:00:00 AM ET
      $STXS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $STXS
    Financials

    Live finance-specific insights

    See more
    • Stereotaxis Reports 2025 First Quarter Financial Results

      ST. LOUIS, May 12, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the first quarter ended March 31, 2025. "We've started the year with solid execution on key commercial and innovation efforts," said David Fischel, Chairman and CEO. "This is a milestone rich year in which we are beginning to demonstrate the tangible reality and commercial impact of our comprehensive innovation strategy." "Key commercial advances include recurring revenue growth, initial commercialization of MAGiC in Europe, successful demonstrations of GenesisX as a rapidly

      5/12/25 4:01:00 PM ET
      $STXS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Stereotaxis to Report First Quarter 2025 Financial Results on May 12, 2025

      ST. LOUIS, April 22, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2025 first quarter on Monday, May 12, 2025 at the close of the U.S. financial markets. The Company will host a conference call and webcast at 4:30 p.m. EST that day to discuss the Company's results and corporate developments. What:Stereotaxis first quarter 2025 financial results conference call  When:Monday, May 12, 2025, at 4:30 p.m. ET (1:30 p.m. PT)  Dial In Number:To access the live call, dial 800-715-9871 (US and Canada) or 1-646-307-1963 (International) a

      4/22/25 7:00:00 AM ET
      $STXS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Stereotaxis Reports 2024 Full Year Financial Results

      ST. LOUIS, March 03, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the fourth quarter and full year ended December 31, 2024. "We have started a milestone rich year in which we will demonstrate the tangible reality of our overall strategic transformation into a company with an easily adopted robot that can navigate a proprietary set of catheters in EP and broadly across endovascular procedures," said David Fischel, Chairman and CEO. "Our progress leads to an expanded clinical impact, scalable capital model, strategic self-sufficiency, and an attractiv

      3/3/25 7:30:00 AM ET
      $STXS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $STXS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Isaac Paul J bought $68,780 worth of shares (38,000 units at $1.81), increasing direct ownership by 77% to 87,299 units (SEC Form 4)

      4 - Stereotaxis, Inc. (0001289340) (Issuer)

      3/11/25 3:38:02 PM ET
      $STXS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Director Isaac Paul J bought $44,836 worth of shares (24,788 units at $1.81), increasing direct ownership by 90% to 49,066 units (SEC Form 4)

      4 - Stereotaxis, Inc. (0001289340) (Issuer)

      3/10/25 10:32:20 AM ET
      $STXS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Director Isaac Paul J bought $15,350 worth of shares (8,095 units at $1.90) (SEC Form 4)

      4 - Stereotaxis, Inc. (0001289340) (Issuer)

      8/20/24 8:38:24 PM ET
      $STXS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $STXS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • ROTH MKM initiated coverage on Stereotaxis with a new price target

      ROTH MKM initiated coverage of Stereotaxis with a rating of Buy and set a new price target of $5.00

      1/10/24 8:16:33 AM ET
      $STXS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Aegis Capital initiated coverage on Stereotaxis with a new price target

      Aegis Capital initiated coverage of Stereotaxis with a rating of Buy and set a new price target of $6.00

      7/12/22 9:20:32 AM ET
      $STXS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • B. Riley Securities initiated coverage on Stereotaxis with a new price target

      B. Riley Securities initiated coverage of Stereotaxis with a rating of Buy and set a new price target of $6.00

      6/23/22 8:13:15 AM ET
      $STXS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $STXS
    SEC Filings

    See more
    • SEC Form SD filed by Stereotaxis Inc.

      SD - Stereotaxis, Inc. (0001289340) (Filer)

      6/2/25 12:07:07 PM ET
      $STXS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Stereotaxis Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Stereotaxis, Inc. (0001289340) (Filer)

      5/19/25 12:13:29 PM ET
      $STXS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 10-Q filed by Stereotaxis Inc.

      10-Q - Stereotaxis, Inc. (0001289340) (Filer)

      5/13/25 4:00:14 PM ET
      $STXS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $STXS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Stereotaxis Inc. (Amendment)

      SC 13G/A - Stereotaxis, Inc. (0001289340) (Subject)

      2/14/24 4:26:22 PM ET
      $STXS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G/A filed by Stereotaxis Inc. (Amendment)

      SC 13G/A - Stereotaxis, Inc. (0001289340) (Subject)

      2/14/23 4:32:50 PM ET
      $STXS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G/A filed by Stereotaxis Inc. (Amendment)

      SC 13G/A - Stereotaxis, Inc. (0001289340) (Subject)

      2/14/22 5:07:16 PM ET
      $STXS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $STXS
    Leadership Updates

    Live Leadership Updates

    See more
    • Stereotaxis Technology to be Featured at Annual Meeting of the Society for Cardiac Robotic Navigation

      ST. LOUIS, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will participate in the Society for Cardiac Robotic Navigation's Annual Meeting taking place October 28-29 in Lisbon, Portugal. The global physician-led Society for Cardiac Robotic Navigation (SCRN) is dedicated to establishing a community and platform for users of robotic technologies in cardiology. The annual SCRN conference provides a venue for physicians and healthcare professionals to share best practices, discuss new clinical literature, and evaluate the latest innovations in technology. The

      10/21/24 8:41:13 AM ET
      $STXS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Stereotaxis Strengthens Board of Directors with Appointment of Nachum Shamir

      ST. LOUIS, July 18, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), a pioneer in surgical robotics for minimally invasive endovascular intervention, today announced the appointment of Nachum "Homi" Shamir to its Board of Directors. Mr. Shamir most recently served as Chairman and Chief Executive Officer of Luminex Corporation from 2014 through its sale to DiaSorin S.p.A. for $1.8 Billion in 2021. Prior to Luminex, Mr. Shamir served as President and Chief Executive Officer of Given Imaging from 2006 through its sale to Covidien for $1 Billion in 2014. He currently serves as Chairman of Mediwound, a publicly-traded leader in enzymatic therapeutics for burn and wound-care, and SSI Diagnosti

      7/18/24 4:13:00 PM ET
      $STXS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Stereotaxis Strengthens Board of Directors with Appointment of Myriam J. Curet, M.D.

      ST. LOUIS, July 26, 2021 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced the appointment of Myriam J. Curet, M.D., to its Board of Directors. Dr. Curet currently serves as Executive Vice President and Chief Medical Officer for Intuitive Surgical, the global leader and pioneer of robotic surgery. Dr. Curet joined Intuitive Surgical in 2005 and has since led the development of clinical evidence, physician education, and reimbursement and regulatory activities that have been instrumental to Intuitive Surgical's growth across multiple clinical specialties. For more than 20 years, Dr. Cu

      7/26/21 9:00:00 AM ET
      $STXS
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care